Systematic review: non-invasive prognostic tests for primary sclerosing cholangitis.
Journal
Alimentary pharmacology & therapeutics
ISSN: 1365-2036
Titre abrégé: Aliment Pharmacol Ther
Pays: England
ID NLM: 8707234
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
received:
04
09
2020
revised:
02
10
2020
accepted:
30
01
2021
pubmed:
21
2
2021
medline:
2
4
2021
entrez:
20
2
2021
Statut:
ppublish
Résumé
Several prognostic tests for primary sclerosing cholangitis (PSC) have been developed, including biochemical models, elastography and magnetic resonance imaging scores. To conduct a systematic review of non-invasive prognostic tests for PSC. A systematic review was conducted from 1987 to 2020 of blood tests, biochemical models, elastography and imaging scores associated with outcomes in PSC. Forty studies of prognostic tests that collectively included 16 094 subjects with PSC were reviewed, of which 26 studies of non-invasive tests including 13 759 subjects with PSC were included. Normalisation or reduction of alkaline phosphatase with or without therapy was associated with transplant-free survival and reduced risk of hepatobiliary cancers but cut-off values for alkaline phosphatase were not consistent among studies. The most studied prognostic biochemical model was the Mayo Risk Score (MRS) evaluated in 18 studies with a c-statistic from 0.63 to 0.85 for clinical outcomes. One study demonstrated that the UK-PSC score outperforms MRS for predicting clinical outcomes with a c-statistics of 0.81and 0.75 respectively. A transient elastography score greater than 11.1 kPa is associated with survival and liver-related complications. The Anali score, derived from specific MRI and MRCP features, is associated with the development of cholangiocarcinoma and decompensated cirrhosis. Promising prognostic models include the enhanced liver fibrosis (ELF) score, ELF test and PREsTo scores. MRS is the most studied prognostic score for clinical outcomes in PSC but the UK-PSC score and PREsTo have better test performance. Further studies comparing MRS to UK-PSC score, PREsTo or ELF with elastography or imaging-based scores are warranted.
Sections du résumé
BACKGROUND
Several prognostic tests for primary sclerosing cholangitis (PSC) have been developed, including biochemical models, elastography and magnetic resonance imaging scores.
AIM
To conduct a systematic review of non-invasive prognostic tests for PSC.
METHODS
A systematic review was conducted from 1987 to 2020 of blood tests, biochemical models, elastography and imaging scores associated with outcomes in PSC.
RESULTS
Forty studies of prognostic tests that collectively included 16 094 subjects with PSC were reviewed, of which 26 studies of non-invasive tests including 13 759 subjects with PSC were included. Normalisation or reduction of alkaline phosphatase with or without therapy was associated with transplant-free survival and reduced risk of hepatobiliary cancers but cut-off values for alkaline phosphatase were not consistent among studies. The most studied prognostic biochemical model was the Mayo Risk Score (MRS) evaluated in 18 studies with a c-statistic from 0.63 to 0.85 for clinical outcomes. One study demonstrated that the UK-PSC score outperforms MRS for predicting clinical outcomes with a c-statistics of 0.81and 0.75 respectively. A transient elastography score greater than 11.1 kPa is associated with survival and liver-related complications. The Anali score, derived from specific MRI and MRCP features, is associated with the development of cholangiocarcinoma and decompensated cirrhosis. Promising prognostic models include the enhanced liver fibrosis (ELF) score, ELF test and PREsTo scores.
CONCLUSION
MRS is the most studied prognostic score for clinical outcomes in PSC but the UK-PSC score and PREsTo have better test performance. Further studies comparing MRS to UK-PSC score, PREsTo or ELF with elastography or imaging-based scores are warranted.
Types de publication
Journal Article
Review
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
774-783Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
© 2021 John Wiley & Sons Ltd.
Références
Charatcharoenwitthaya P, Lindor KD. Primary sclerosing cholangitis: patients with a rising alkaline phosphatase at annual follow-up. Clin Gastroenterol Hepatol. 2007;5:32-36.
Boonstra K, Weersma RK, van Erpecum KJ, et al. Population-based epidemiology, malignancy risk and outcome of primary sclerosing cholangitis. Hepatology. 2013;58(6):2045-2055.
Dyson JK, Beuers U, Jones DEJ, et al. Primary sclerosing cholangitis. Lancet. 2018;391:2547-2559.
Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Systematic Reviews. 2015;4:1-9.
Moons KGM, Wolff RF, Riley RD, et al. PROBAST: a tool to assess risk of bias and applicability of prediction model studies: explanation and elaboration. Ann Intern Med. 2019;170:51-58.
Stanich PP, Björnsson E, Gossard AA, et al. Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitis. Digestive Liver Disease. 2011;43(4):309-313.
Hilscher M, Enders FB, Carey EJ, et al. Alkaline phosphatase normalization is a biomarker of improved survival in primary sclerosing cholangitis. Ann Hepatol. 2016;15(2):246-253.
Rupp C, Rössler A, Halibasic E, et al. Reduction in alkaline phosphatase is associated with longer survival in primary sclerosing cholangitis, independent of dominant stenosis. Aliment Pharmacol Ther. 2014;40:1292-1301.
Al Mamari S, Djordjevic J, Halliday JS, et al. Improvement of serum alkaline phosphatase to <1.5 upper limit of normal predicts better outcome and reduced risk of cholangiocarcinoma in primary sclerosing cholangitis. J Hepatol. 2013;58:329-334.
Lindström L, Hultcrantz R, Boberg KM, Friis-Liby I, Bergquist A. Association between reduced levels of alkaline phosphatase and survival times of patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol. 2013;11:841-846.
Vesterhus M, Hov JR, Holm A, et al. Enhanced liver fibrosis score predicts transplant-free survival in primary sclerosing cholangitis. Hepatology. 2015;62:188-197.
Goode EC, Clark AB, Mells GF, et al. Factors associated with outcomes of patients with primary sclerosing cholangitis and development and validation of a risk scoring system. Hepatology. 2019;69(5):2120-2135.
de Vries EM, Wang J, Williamson KD, et al. A novel prognostic model for transplant-free survival in primary sclerosing cholangitis. Gut. 2018;67:1864-1869.
Eaton JE, Vesterhus M, McCauley BM, et al. Primary sclerosing cholangitis risk estimate tool (PREsTo) predicts outcomes of the disease: a derivation and validation study using machine learning. Hepatology. 2020;71:214-224.
Saffioti F, Roccarina D, Vesterhus M, et al. Cholangiocarcinoma is associated with a raised enhanced liver fibrosis score independent of primary sclerosing cholangitis. Eur J Clin Invest. 2019;49:e13088.
Weismüller TJ, Trivedi PJ, Bergquist A, et al. Patient age, sex, and inflammatory bowel disease phenotype associate with course of primary sclerosing cholangitis. Gastroenterology. 2017;152:1975-1984.
Kim WR, Therneau TM, Wiesner RH, et al. A revised natural history model for primary sclerosing cholangitis. Mayo Clin Proc. 2000;75:688-694.
Helzberg JH, Petersen JM, Boyer JL. Improved survival with primary sclerosing cholangitis: a review of clinicopathologic features and comparison of symptomatic and asymptomatic patients. Gastroenterology. 1987;92:1869-1875.
Song C, Lewis S, Kamath A, et al. Primary sclerosing cholangitis: diagnostic performance of MRI compared to blood tests and clinical scoring systems for the evaluation of histopathological severity of disease. Abdominal Radiology. 2020;45:354-364.
Cazzagon N, Lemoinne S, El Mouhadi S, et al. The Complementary Value of MRI and VCTE Stratification in PSC. Am J Gastro. 2019;114:1878-1885.
Lemoinne S, Cazzagon N, El Mouhadi S, et al. Simple MR scores associate with outcomes of patients with PSC. Clin Gastroenterol Hepatol. 2019;17:2785-2792.
Corpechot C, Gaouar F, El Naggar A, et al. Baseline values and changes in liver stiffness measured by transient elastography are associated with severity of fibrosis and outcomes of patients with primary sclerosing cholangitis. Gastroenterology. 2014;146:970-979.
Eaton JE, Sen A, Hoodeshenas S, et al. Changes in liver stiffness, measured by MRE associated with hepatic decompensation in patients with primary sclerosing cholangitis. Clin Gastro Hepatol. 2020;18:1576-1583.
Ruiz A, Lemoinne S, Carrat F, et al. Radiologic course of primary sclerosing cholangitis: assessment by three-dimensional magnetic resonance cholangiography and predictive features of progression. Hepatology. 2014;59:242-250.
Masuoka HC, Vuppalanchi R, Deppe R, et al. Individuals with primary sclerosing cholangitis have elevated levels of biomarkers for apoptosis but not necrosis. Dig Dis Sci. 2015;60:3642-3646.
Voigtländer T, Wlecke J, Negm AA, et al. Calprotectin in bile a disease severity marker in patients with primary sclerosing cholangitis. J Clin Gastroenterol. 2014;48:866-869.
Wunsch E, Krawczyk M, Milkiewicz M, et al. Serum autotaxin is a marker of the severity of liver disease and overall survival in patients with cholestatic liver diseases. Sci Rep. 2016;6:1-12.
Dhillon AK, Kummen M, Troseid M, et al. Circulating markers of gut barrier dysfunction associated with disease severity in primary sclerosing cholangitis. Liver International. 2018;39(2):371-381.
Tornai T, Palyu E, Vitalis Z, et al. Gut barrier failure biomarkers are associated with poor disease outcome in patients with primary sclerosing cholangitis. World J Gastroenterol. 2017;23(29):5412-5421.
Friedrich K, Baumann C, Wannhoff A, et al. Serum mi-RNA is an independent biomarker of survival in patients with primary sclerosing cholangitis. J Gastro Liver Dis. 2018;27(2):145-150.
Dhillon AK, Kremer AE, Kummen M, et al. Autotaxin activity predicts transplant-free survival in primary sclerosing cholangitis. Sci Rep. 2019;9:1-10.
Steyerberg EW, Moons KGM, van der Windt DA, et al. Prognosis research strategy (PROGRESS) 3: prognostic model research. PLoS Medicine. 2013;10:e1001381.
Muir AJ, Levy C, Janssen HLA, et al. Simtuzumab for primary sclerosing cholangitis: phase 2 study results with insights on the natural history of the disease. Hepatology. 2019;69:684-698.
Rudolph G, Gotthardt D, Klöters-Plachky P, et al. Influence of dominant bile duct stenoses and biliary infections on outcome in primary sclerosing cholangitis. J Hepatol. 2009;51:149-155.
Lindor KD, Kowdley KV, Harrison ME. ACG clinical guideline: Primary sclerosing cholangitis. Am J Gastroenterol. 2015;110:646-659.
Allegretti JR, Kassam Z, Carrellas M, et al. “Fecal microbiota transplantation in patients with primary sclerosing cholangitis: a pilot clinical trial. Am J Gastroenterol. 2018;114(7):1071-1079.